◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
首页 › 全部股票 › 4502 · English version

Takeda Pharmaceutical Company Limited (4502)

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街（美国） · 最近更新： 2026-08-11

武田药品工业株式会社从事药品的研究、开发、制造、营销和授权。它提供胃肠病学、罕见疾病、血浆衍生疗法、肿瘤学、疫苗和神经科学领域的药品。该公司提供的产品有 Entyvio、Gattex/Revestive、Takecab/Vocinti、EOHILIA、Takhzyro、Advate、Elaprase、Replagal、Vpriv、Adynovate/Adynovi、Livtencity、ADZYNMA、Gammagard Liquid/Kiovig、Hyqvia、Cuvitru、Flexbumin、Adcetris、Leuplin/Enantone、Ninlaro、 Iclusig、FRUZAQLA、Alunbrig、vyvanse/elvanse、Trintellix 和 QDENGA 品牌。它与 Arrowhead Pharmaceuticals、Cour Pharmaceuticals、Engitix、Halozyme、Mirum Pharmaceuticals、UCSD/Fortis Advisors、Zedira/Dr. 拥有产品开发和商业化的许可和合作。

机器翻译

关键数据

查看交互式图表与完整报表 →

年度利润表

利润表2026-03-312025-03-312024-03-312023-03-31
总收入JPY 4.51TJPY 4.58TJPY 4.26TJPY 4.03T
毛利JPY 2.93TJPY 3.00TJPY 2.84TJPY 2.78T
营业利润（EBIT）JPY 464.5BJPY 466.4BJPY 309.9BJPY 587.8B
净利(JPY 152.4B)JPY 107.9BJPY 144.1BJPY 317.0B

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 4502 交互式查看器。 /companies/us/4502

类似公司

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.